Jump to content

GVAX Not an Option, Chemo Question??

Andrea B.

Recommended Posts

Hi All,

Well the bad news continues for us...my mom is not eligible for the GVAX vaccine due to the fact that there is not cancer in the fluid around her lung. Can't believe I would ever wish for cancer to be present!!! Also, the cancer in her liver is rapidly progressing and one of her liver blood counts is high. :(

So right now the only other option to pursue is another chemo. Her oncologist mentioned trying Navalbine, but I am wondering if any others of you have suggestions on ones to try. Thanks so much! This site is a saving grace for me. Blessings to each of you.

Andrea B.

Link to comment
Share on other sites

The article below is about combined Gemzar (gemcitabine) /Navalbine (vinorelbine)

http://www.ncbi.nlm.nih.gov/entrez/quer ... t=Abstract

Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy.

Chen YM, Perng RP, Lee CS, Lin WC, Tsai CM, Whang-Peng J.

Chest Department, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University, Taipei 112, Taiwan, ROC.

Both gemcitabine and vinorelbine are new anticancer drugs that have shown activity in the treatment of chemonaive non-small-cell lung cancer (NSCLC). Their role in the second-line treatment of NSCLC is less clear. We conducted a phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with NSCLC who had not responded to previous platinum-based chemotherapy, to assess the response and toxicity of this regimen. Seventeen patients were enrolled from September 1998 to February 2001. Treatment consisted of vinorelbine 20 mg/m2 and gemcitabine 800 mg/m2 intravenous infusion on days 1, 8, and 15 every 4 weeks. Sixty-five cycles of treatment were given, with a median of four cycles. All patients were evaluable for the toxicity profile, and 16 patients were evaluable for the response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (52.9%) during treatment. Febrile neutropenia occurred in only 1 patient (5.9%). Grade III anemia and thrombocytopenia occurred in two and three patients, respectively. Other toxicities were few and mild in severity. After 2 cycles of treatment, 5 of 16 patients (31.3%) had a partial response (95% CI 8.6-64%). The median time to disease progression was 4.6 months and the median survival was 8.3 months. The 1-year survival rate was 34.3%. In conclusion, gemcitabine and vinorelbine salvage chemotherapy produces a relatively high response rate, low toxicity profile, and good survival in Chinese patients with NSCLC who have not responded to previous platinum-based chemotherapy. Further study is needed to confirm its activity.

Publication Types:

Clinical Trial

Clinical Trial, Phase II

There are other clinical trials for nsclc that is refractory

http://www.clinicaltrials.gov/ct/search ... refractory

MAC-321 is a new chemo.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.